These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34228562)

  • 1. An Observational Study of Different Treatment Practices for Aggressive Posterior Retinopathy of Prematurity.
    Kumari A; Surve A; Azad SV; Chawla R; Chandra P; Thukral A; Vohra R; Kumar A
    J Pediatr Ophthalmol Strabismus; 2021; 58(6):370-376. PubMed ID: 34228562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.
    Sen P; Agarwal AAK; Bhende P; Ganesan S
    Int Ophthalmol; 2022 Jan; 42(1):95-101. PubMed ID: 34415476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
    Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
    Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.
    Shah PK; Subramanian P; Venkatapathy N; Chan RVP; Chiang MF; Campbell JP
    J AAPOS; 2019 Oct; 23(5):264.e1-264.e4. PubMed ID: 31521847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity.
    Gundlach BS; Kokhanov A; Altendahl M; Suh SY; Fung S; Demer J; Pineles S; Khitri M; Chu A; Tsui I
    Am J Ophthalmol; 2022 Jun; 238():86-96. PubMed ID: 34788594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Outcomes Between Combined Sparing Laser Photocoagulation and Intravitreal Bevacizumab Treatment Versus Conventional Laser Photocoagulation in Aggressive Posterior Retinopathy of Prematurity.
    Ittarat M
    J Pediatr Ophthalmol Strabismus; 2021; 58(5):292-297. PubMed ID: 34180288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic clinical features associated with aggressive posterior retinopathy of prematurity.
    Ahn YJ; Hong KE; Yum HR; Lee JH; Kim KS; Youn YA; Park SH
    Eye (Lond); 2017 Jun; 31(6):924-930. PubMed ID: 28234354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.
    Prajapati V; Choudhary T; Chauhan W; Shah S; Handa R; Jahan B; Malviya S; Sengupta S
    Indian J Ophthalmol; 2023 Feb; 71(2):411-415. PubMed ID: 36727329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.